In an age where everything is digital, and buying shares no longer means having to physically take delivery of paper share certificates, it’s tempting to assume you can deal at the touch of a button at any time during the day and get the same price you see on your screen. However, that price is just an illusion which lasts only the time it takes the market to match similar-sized buyers and ...

- Rare disease drug eplontersen delivers positive trial results - FDA application expected in 2022 - Multi-billion-dollar market potential Pharmaceutical giant AstraZeneca (AZN) said a Phase III study of eplontersen to treat a rare heart disease had delivered positive results. The drug achieved statistically significant and clinically meaningful reduction of the transthyretin ...

Increasing life expectancy means we are living for longer than ever before. According to Office for National Statistics data, people aged 65 in 2020 on average can expect to live for another 20 years or more, and for those in very good health, it’s statistically quite possible that many will hit 100 years of age. We will need financial support when we stop working and the state pension is ...

A lot of water has passed under the bridge since one-time star fund manager Mark Barnett was replaced at the helm of Edinburgh Investment Trust (EDIN) – a global pandemic, a stock market collapse and widespread overhaul of the portfolio. Now almost three years on, the results speak for themselves and Shares believes investors can expect more of the same in the years ahead. Since Majedie ...

- Strong efficacy for metastatic breast cancer treatment Enhertu - Reducing disease progression by 50% and death by 36% - Potential for $3 billion of additional sales Pharmaceutical company AstraZeneca (AZN) announced its metastatic breast cancer treatment Enhertu had demonstrated ‘superior and clinically meaningful progression free survival’ reducing the risk of disease progression ...

-Rapid Covid-19 test gets UK approval -Saliva-based Covid-19 test launches across EEA -UK application submitted International specialist diagnostics company Novacyt (NCYT:AIM) has become one of the first companies to launch a saliva-based rapid antigen self-test after receiving a CE mark. This means it can be marketed across all 30 EEA countries. (European Economic Area) The test ...

Pharmaceutical giant AstraZeneca (AZN) made a strong start to 2022, reporting first quarter revenues up 60% to $11.39 billion and core EPS up 20% to $1.89. The increase in revenues was due to growth across the company’s drug franchises as well as a contribution from Alexion medicines and several Covid-19 contracts expected to be delivered in the first half. The company said a ...

A significant number of FTSE 100 companies could face shareholder rebellion over the coming weeks as investors increasingly put pressure on boards over key issues. There is a long list of topics which could dominate this year’s annual shareholder meeting season, which gets into full swing at the end of April. These include environmental policy and climate change action, boardroom and ...

Shares in pharmaceutical group AstraZeneca (AZN) are trading at a record high and it is battling Shell (SHEL) to be the largest company by value on the UK stock market. There are plenty of reasons to expect shareholders to receive further rewards in time, given a packed schedule of new treatment launches which could help underpin double-digit revenue growth, improved margins and bumper cash ...

Recession concerns have been seeping into the investment narrative in recent weeks. The war in Ukraine has exacerbated supply shortages and added unexpected fuel to the inflationary fire. Inflation in basic non-discretionary goods crimps spending elsewhere and could put a big dent in the expected nascent global recovery. While recession isn’t the base case for most economists, investors ...

Pharmaceutical giant AstraZeneca (AZN) has received marketing authorization from the EU for its Covid-19 prevention drug Evusheld, previously known as AZD7442. It can be used across a broad population of adults and adolescents aged 12 or older, weighing more than 40 kilos. Importantly, AstraZeneca said the drug, which is composed of a long-acting antibody combination, retains neutralizing ...

Investors followed upbeat drugs data from pharmaceutical giant AstraZeneca (AZN) pushing the stock towards the top of the FTSE 100 leader board on Tuesday (15 February 2022). Astra reported positive results from Phase III trials of cancer drug Lynparza which showed a reduced risk of disease progression in castration resistant prostate cancer by a third. The shares rallied more than 3% to ...

Pharmaceutical giant AstraZeneca (AZN) beat forecasts on Thursday after reporting full year revenues and profit around 5% ahead of expectations. Astra shares rose 3% to £86.42 on Thursday (10 February 2022). Product sales grew 38% in constant currencies to $36.54 billion and core earnings per share jumped 37% to $5.29, compared with market expectations of $4.97. The stand-out performance ...

The FTSE 100 closed Wednesday’s session with a modest gain, edging 0.16% higher to 7,516.87 points on ongoing optimism over the impact of the less severe Omicron strain and support from a solid ADP private sector payrolls report across the pond, which prepared investors for a decent non-farm payrolls print on Friday. Blue chip miners Rio Tinto (RIO) and BHP (BHP), banks Lloyds (LLOY) and ...

By midday on Wednesday, London’s FTSE 100 had shaken off its earlier losses and resumed the upwards momentum it displayed on its first trading day of 2022, as broker upgrades helped lift some heavyweight stocks and supermarkets gained ground on positive industry data. The blue chip benchmark traded 0.19% higher at 7,519.62 by lunchtime, though the FTSE 250 was flat at 23,895.60. Investors ...

UK stocks started the shortened trading week in good spirits with the FTSE 100 index of leading stocks up 60 points or 0.8% at midday to 7,432, having touched a new year-high of 7,457 points in early trading. Leadership shifted from consumer-oriented stocks in early deals to healthcare and engineering stocks by lunchtime. In Asia, shares fell overnight as investors continues to fret over the ...

Shares in pharmaceutical giant AstraZeneca (AZN) gained 0.9% to £86.85 after the company sealed a commercialization agreement with Ionis Pharmaceuticals for the development and sale of eplonsteren which is in late stage trials. The companies have agreed to jointly develop the drug in the US while Astra will develop and commercialise it in the rest of the world except Latin America. The ...

UK stocks began the shortened trading week on the front foot with the FTSE 100 up 65 points or 0.9% to a new year-high of 7,437 points in early trading. Leading the market higher were domestically oriented consumer and financial stocks including retailers AB Foods (ABF), Next (NXT) and high street bank Lloyds (LLOY). Shares in Asia fell overnight as investors continues to fret over the ...

London’s FTSE 100 edged 0.21% higher to 7,356.94 points on the last full trading day before Christmas, as investors welcomed news that the Omicron variant may not be as severe as previous strains. Citing data from an Oxford University laboratory study, drugs giant AstraZeneca (AZN) said a three dose course of its Covid-19 vaccine is effective against the highly transmissible new ...

UK stocks rallied in early trading on what commentators called ‘turnaround Tuesday’ following back-to back losses for markets on Friday and Monday, helped by positive US earnings reports overnight. Chip maker Micron reported strong first quarter results due to robust demand from new product areas like data centres, electric vehicles and factory automation, while footwear giant Nike posted ...